Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
5.77
-0.14 (-2.37%)
Mar 30, 2026, 4:00 PM EDT - Market closed
Fennec Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts that cover Fennec Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $15, which forecasts a 159.97% increase in the stock price over the next year. The lowest target is $13 and the highest is $18.
Price Target: $15 (+159.97%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
The average analyst rating for Fennec Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $18 | Buy | Initiates | $18 | +211.96% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +125.30% | Aug 21, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $13 → $14 | Strong Buy | Maintains | $13 → $14 | +142.63% | Aug 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $13 | Strong Buy | Reiterates | $13 | +125.30% | May 20, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $13 | Strong Buy | Maintains | $12 → $13 | +125.30% | May 14, 2025 |
Financial Forecast
Revenue This Year
78.49M
from 44.64M
Increased by 75.81%
Revenue Next Year
98.16M
from 78.49M
Increased by 25.06%
EPS This Year
0.67
from -0.34
EPS Next Year
1.13
from 0.67
Increased by 67.06%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 91.3M | 120.3M | |||
| Avg | 78.5M | 98.2M | |||
| Low | 59.4M | 80.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 104.6% | 53.3% | |||
| Avg | 75.8% | 25.1% | |||
| Low | 33.0% | 2.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|
| High | 1.04 | 1.67 | ||
| Avg | 0.67 | 1.13 | ||
| Low | 0.37 | 0.87 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2029 | 2030 |
|---|---|---|---|---|
| High | - | 147.5% | ||
| Avg | - | 67.1% | ||
| Low | - | 29.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.